Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Company Overview

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials. In parallel, Acrivon is advancing additional stapled-peptide programs directed at other oncogenic KRAS mutants such as G12D, with the goal of expanding its pipeline to address multiple unmet needs in solid tumor oncology.

Acrivon was established in 2021 as a spin-out from Calibr, the drug discovery division of The Scripps Research Institute, and is headquartered in Redwood City, California. The company leverages its origin in academic research to maintain close collaborations with leading cancer centers and translational science groups across North America and Europe.

Supported by a management team with extensive experience in biotechnology and pharmaceutical drug development, Acrivon is building strategic partnerships and advancing its peptide platform to potentially deliver first-in-class or best-in-class therapies for patients with RAS-mutant cancers. The company continues to focus on rigorous clinical development and regulatory engagement to bring novel peptide-based oncology treatments to market.

Key Stats

• Today's Range: $2.04 to $2.14
• 50-Day Range: $1.29 to $2.08
• 52-Week Range: $1.05 to $3.56
• Volume: 165,851 shs
• Average Volume: 1.48 million shs
• Market Capitalization: $90.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.67
• Consensus Rating: Moderate Buy

Acrivon Therapeutics Stock Analysis - MarketRank™

Acrivon Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 636th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Acrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Acrivon Therapeutics has a consensus price target of $11.67, representing about 449.0% upside from its current price of $2.13.

Amount of Analyst Coverage

Acrivon Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acrivon Therapeutics are expected to grow in the coming year, from ($2.00) to ($1.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acrivon Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acrivon Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acrivon Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.00% of the float of Acrivon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Acrivon Therapeutics has a short interest ratio ("days to cover") of 4.16.

Change versus previous month

Short interest in Acrivon Therapeutics has recently increased by 9.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acrivon Therapeutics does not currently pay a dividend.

Dividend Growth

Acrivon Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Acrivon Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 7 people have searched for ACRV on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.50% of the stock of Acrivon Therapeutics is held by insiders.

Percentage Held by Institutions

71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACRV Stock Analysis - Frequently Asked Questions

How have ACRV shares performed this year?

Acrivon Therapeutics' stock was trading at $2.41 at the beginning of 2026. Since then, ACRV shares have decreased by 11.8% and is now trading at $2.1250.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its quarterly earnings results on Thursday, March, 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49).

When did Acrivon Therapeutics IPO?

Acrivon Therapeutics (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acrivon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/19/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACRV
• CIK: 1781174
• Web: www.acrivon.com
• Phone: 617-207-8979
• Fax: N/A
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acrivon Therapeutics: $11.67
• High Price Target: $19.00
• Low Price Target: $8.00
• Potential Upside/Downside: +449.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.23%
• Return on Assets: -51.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.69
• Quick Ratio: 7.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.57 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 42,800,000
• Free Float: 35,451,000
• Market Cap: $90.95 million
• Optionable: Not Optionable
• Beta: 2.01